



**“Evolution of Translational PK/PD: A Pharma Perspective”**

*Presented by:*

**Lisa J. Benincosa, PhD '93**

Vice President and Global Head of DMPK and Bioanalytical R&D

Deputy Head Pharmaceutical Sciences

Roche Pharmaceutical Research and Early Development

Roche Innovation Center Basel

**Lisa Benincosa** is Vice President and Global Head, DMPK and Bioanalytical R&D, in Pharmaceutical Sciences Department, Roche Pharmaceutical Research and Early Development in Basel Switzerland. She received her BS degree in Pharmacy (1987) from West Virginia University and Ph.D. (1993) from the University at Buffalo, State University of New York. In 1992, Dr. Benincosa joined the Clinical Pharmacokinetic Department at SmithKline Beecham Pharmaceuticals where she rose to position of Section Head with additional global responsibility for preclinical and clinical PK/PD with focus on infectious disease, respiratory and metabolic diseases. She joined Pfizer in 2001 as Director in Clinical Pharmacokinetics/Pharmacodynamics and became Executive Director and Groton/New London Clinical Pharmacology Site Head in 2003. Dr. Benincosa joined Roche in 2009 and is currently Deputy Head Pharmaceutical Sciences and Global Head of DMPK and Bioanalytical R&D at Roche Innovation Center in Basel. She has received leadership awards over her career such as Pfizer People Leader Award in 2007, the Tribute to Women & Industry Award in 2012 and Leadership Excellence Award from Roche pRED in 2016. She has been named to the WVU School of Pharmacy inaugural Hall of Fame. Over the course of her career in the pharmaceutical industry, she has contributed to preclinical and clinical regulatory filings across various therapeutic areas. She has served as a member of the SUNY Buffalo School of Pharmacy and Pharmaceutical Sciences Dean's Advisory Council and serves on the Leadership Council, Center for Pharmacometrics and Systems Pharmacology, University of Florida College of Pharmacy. She has presented externally on integration of PK/PD in drug research and development at national scientific meetings, such as, ASCPT and ISSX and on dose selection in antimicrobial drug development at the FDA/IDSA/ISAP public workshop. She has presented on translational PK/PD in the Clinical Investigator Training Program Harvard Medical School, University at Buffalo Pharmaceutics Symposium and UCSF Schools of Pharmacy and Medicine Symposium and contributor to the AAPS Translational Sciences 101 eCourse. She is a long standing member of AAPS and ASCPT and has served on various committees for these organizations.



David C. K. Chu, PhD

**David C. K. Chu, PhD** is Distinguished Research Professor, Emeritus, of Pharmaceutical and Biomedical Sciences at the College of Pharmacy, University of Georgia. He obtained his PhD in Medicinal Chemistry from the University at Buffalo in 1975 under the mentorship of Professor Thomas Bardos. Dr. Chu has published over 300 drug discovery related scientific papers and over 50 US patents have been awarded to him. Several of his invented compounds are undergoing clinical trials in the therapeutic areas of cancer, hepatitis B virus, HIV and shingles. An elected member of American Association of Advancement of Science, Dr. Chu received a MERIT Award from the NIH in 2001, and the UGA Inventor of the Year Award in 2002. He will receive the University at Buffalo School of Pharmacy and Pharmaceutical Sciences' most distinguished recognition, the Willis G. Gregory Alumni Award, in April 2017.